Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-1.55% $24.77
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 330.66 mill |
EPS: | -2.76 |
P/E: | -8.97 |
Earnings Date: | Apr 28, 2024 |
SharesOutstanding: | 53.72 mill |
Avg Daily Volume: | 0.823 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.97 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.53x |
Company: PE -8.97 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 23.11 - 26.43 ( +/- 6.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Ford David A | Buy | 85 000 | Stock Option (Right to Buy) |
2024-03-01 | Ford David A | Buy | 0 | |
2024-02-27 | Zago Wagner M. | Buy | 85 000 | Stock Option (Right to Buy) |
2024-02-27 | Walker Karin L | Buy | 54 000 | Stock Option (Right to Buy) |
2024-02-27 | Smith Brandon S. | Buy | 85 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
77.45 |
Last 98 transactions |
Buy: 1 184 000 | Sell: 192 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $24.77 (-1.55% ) |
Volume | 0.773 mill |
Avg. Vol. | 0.823 mill |
% of Avg. Vol | 93.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $27.29 | N/A | Active |
---|
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Date | Signal | @ |
---|---|---|
WBTUSD | Mar 28 - 18:43 | 8.37 |
TRXUSD | Mar 28 - 18:39 | $0.120 |
XMRUSD | Mar 28 - 18:34 | $135.06 |
IONUSD | Mar 28 - 18:23 | 454.85 |
APE18876USD | Mar 28 - 18:21 | 2.02 |
DAOUSD | Mar 28 - 18:19 | $1.823 |
TONUSD | Mar 28 - 18:13 | 4.88 |
STXUSD | Mar 28 - 18:19 | $3.43 |
SFRXETHUSD | Mar 28 - 18:15 | 3 791.50 |
BTC.BUSD | Mar 28 - 18:14 | 70 390 |